ASCO20 Virtual Scientific Program
May 29 – 31, 2020

Booth Visit our on-demand Industry Expert Theater for an informative presentation on the potential use of Oncotype DX Breast Recurrence Score test during the COVID-19 pandemic when surgeries for patients with early-stage breast cancer are being delayed:

Speaker Dr. Christy Russell, MD Breast Cancer Management During the Covid-19 Pandemic
Speaker: Christy Russell, MD, Senior Medical Affairs Director, Precision Oncology, Exact Sciences


See new data for the Oncotype DX Breast Recurrence Score test and how it changes treatment decisions for patients with early-stage breast cancer.

  • New Oncotype DX® Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results
  • Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020
  • On-Demand Virtual Posters of Interest

    Practice-changing use of the 21-gene Oncotype DX Breast Recurrence Score assay in a public hospital in Brazil: Results of 155 cases
    e-12518 | Andre Mattar
    Practice-changing use of the 21-gene Oncotype DX Breast Recurrence Score test in Latin American hospitals
    e-12539 | Henry Gomez
    21-gene Recurrence Score assay as a predictor of pathological response in neoadjuvant CT administration for ER+/HER2- early stage breast cancer
    e-12630 | Serafin M. Murillo
    Economic evaluation of the Oncotype DX test for HR+ early stage breast cancer from the Brazilian societal perspective
    e-19380 | Andre Mattar
    Response to neoadjuvant CT and the 21-gene Breast Recurrence Score in young women with ER+ early breast cancer
    Abstract 514, Poster 6 | Tal Sella | Poster discussion
    Real-world analysis of clinical and economic impact of 21-gene Recurrence Score testing in early-stage breast cancer in Ireland
    Abstract 540, Poster 32 | Lynda McSorley | Virtual poster
    Expanding Criteria for Prognostic Stage IA Disease in HR+ Breast Cancer
    Abstract 550, Poster 42 | Olga Kantor | Virtual poster
    Prediction of response to neoadjuvant hormonal therapy using upfront Oncotype DX Recurrence Score: Results from the SAFIA phase III trial
    Abstract 594, Poster 86 | Khalid Al-Saleh | Virtual poster
    ADAPTcycle: Adjuvant dynamic marker-adjusted, personalized therapy comparing ET + ribociclib vs CT in intermediate-risk HR+/HER2- early breast cancer
    Abstract TPS601, Poster 93 | Nadia Harbeck | Virtual poster
    Early discontinuation to adjuvant ET in the ECOG-ACRIN TAILORx Trial
    Abstract 7004 | Betina Yanez | Oral Abstract
    Breast cancer patients' insurance status correlates with their adherence to ET: Analysis of ECOG-ACRIN TAILORx Trial
    Abstract 7041, Poster 313 | Gelareh Sadigh | Virtual poster

    Making cancer care smarter.™
    X

    We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.